Bone Mineral Density in Children and Adolescents With Prader-Willi Syndrome

Autor: Nitash Zwaveling-Soonawala, Dederieke A. M. Festen, R. J. Kuppens, M. van Leeuwen, G. C. B. (Karen) Bindels-de Heus, Danny A. J. P. Haring, Euphemia C. A. M. Houdijk, L. Lunshof, R. J. Odink, R. F. A. Tummers-de Lind van Wijngaarden, Wilma Oostdijk, M. E. J. Wegdam-den Boer, Petr E. Jira, Anita C. S. Hokken-Koelega, J. J. G. Hoorweg-Nijman, Gianni Bocca, Elbrich P. C. Siemensma, A. A. E. M. Van Alfen, Joost Rotteveel, H. Van Wieringen, N. E. Bakker
Přispěvatelé: Pediatrics, Child and Adolescent Psychiatry / Psychology, General Practice, Erasmus MC other, Other departments, Other Research, Graduate School, Paediatric Endocrinology, Pediatric surgery, ICaR - Circulation and metabolism
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Male
congenital
hereditary
and neonatal diseases and abnormalities

medicine.medical_specialty
Longitudinal study
Time Factors
BODY-COMPOSITION
Adolescent
Endocrinology
Diabetes and Metabolism

Clinical Biochemistry
Context (language use)
METABOLISM
Biochemistry
THERAPY
law.invention
Endocrinology
HEIGHT
Randomized controlled trial
Bone Density
law
Internal medicine
YOUNG-ADULTS
medicine
Humans
Longitudinal Studies
Young adult
Child
Gonadal Steroid Hormones
Netherlands
Bone mineral
Human Growth Hormone
business.industry
Puberty
Biochemistry (medical)
nutritional and metabolic diseases
X-RAY ABSORPTIOMETRY
RANDOMIZED CONTROLLED-TRIAL
LEAN MASS
nervous system diseases
Growth hormone treatment
ESTROGEN
Child
Preschool

Cohort
GH DEFICIENCY
Body Composition
Lean body mass
Female
business
Prader-Willi Syndrome
Zdroj: Journal of Clinical Endocrinology and Metabolism, 100(4), 1609-1618. Endocrine Society
Journal of Clinical Endocrinology and Metabolism, 100(4), 1609-1618
Bakker, N E, Kuppens, R J, Siemensma, E P C, van Wijngaarden, R F A T, Festen, D A M, Bindels-de Heus, G C B, Bocca, G, Haring, D A J P, Hoorweg-Nijman, J J G, Houdijk, E C A M, Jira, P E, Lunshof, L, Odink, R J, Oostdijk, W, Rotteveel, J, Van Alfen, A A E M, van Leeuwen, M, van Wieringen, H, Wegdam-den Boer, M E J, Zwaveling-Soonawala, N & Hokken-Koelega, A C S 2015, ' Bone Mineral Density in Children and Adolescents With Prader-Willi Syndrome: A Longitudinal Study During Puberty and 9 Years of Growth Hormone Treatment ', Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 4, pp. 1609-1618 . https://doi.org/10.1210/jc.2014-4347
Journal of clinical endocrinology and metabolism, 100(4), 1609-1618. The Endocrine Society
Journal of Clinical Endocrinology and Metabolism, 100(4), 1609-1618. The Endocrine Society
Journal of Clinical Endocrinology and Metabolism, 100(4), 1609-1618. ENDOCRINE SOC
ISSN: 0021-972X
DOI: 10.1210/jc.2014-4347
Popis: Context: Longitudinal data on bone mineral density(BMD) in children and adolescents with Prader-Willi Syndrome (PWS) during long-term GH treatment are not available.Objective: This study aimed to determine effects of long-term GH treatment and puberty on BMD of total body (BMDTB), lumbar spine (BMDLS), and bone mineral apparent density of the lumbar spine (BMAD(LS)) in children with PWS.Design and Setting: This was a prospective longitudinal study of a Dutch PWS cohort.Participants: Seventy-seven children with PWS who remained prepubertal during GH treatment for 4 years and 64 children with PWS who received GH treatment for 9 years participated in the study.Intervention: The children received GH treatment, 1 mg/m(2)/day (congruent to 0.035 mg/kg/d).Main Outcome Measures: BMDTB, BMDLS, and BMAD(LS) was measured by using the same dual-energy x-ray absorptiometry machine for all annual measurements.Results: In the prepubertal group, BMDTB standard deviation score (SDS) and BMDLSSDS significantly increased during 4 years of GH treatment whereas BMAD(LS)SDS remained stable. During adolescence, BMDTBSDS and BMAD(LS)SDS decreased significantly, in girls from the age of 11 years and in boys from the ages of 14 and 16 years, respectively, but all BMD parameters remained within the normal range. Higher Tanner stages tended to be associated with lower BMDTBSDS (P = .083) and a significantly lowerBMAD(LS)SDS (P = .016). After 9 years of GH treatment, lean body mass SDS was the most powerful predictor of BMDTBSDS and BMDLSSDS in adolescents with PWS.Conclusions: This long-term GH study demonstrates that BMDTB, BMDLS, and BMAD(LS) remain stable in prepubertal children with PWS but decreases during adolescence, parallel to incomplete pubertal development. Based on our findings, clinicians should start sex hormone therapy from the age of 11 years in girls and 14 years in boys unless there is a normal progression of puberty.
Databáze: OpenAIRE